NeuroSense Therapeutics Receives Nasdaq Noncompliance Notice; Co. Plans To Appeal

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) received a noncompliance notice from Nasdaq on October 1, 2026, due to its failure to meet the minimum market value of listed securities requirement of $35 million. The company plans to appeal this determination by requesting a hearing before the Nasdaq Hearings Panel to seek additional time for compliance.